Detail akcie Biosyent Inc online

Business Summary: BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Biosyent Inc revenues increased 27% to C$33.4M. Net income increased 24% to C$7M. Revenues reflect Pharmaceutical Business segment increase of 25% to C$31.5M, Insecticide Business segment increase of 73% to C$1.9M. Net income was partially offset by Advertising, promotion and sales people increase of 18% to C$5.1M (expense), Employee cost increase of 13% to C$4.7M (expense).